Member Info for Mithun

Good luck all

To buy good luck all. The gates have opened!

https://zakmir.com/stock-market-watch-val-ufo-wsbn/#gs.ejueu2

18.5p to buy moving up nicely

Looks like its holding well from yesterday's rise. Should hooefully push up soon. Gla

Think today is the last chance to get in the teens. 20p plus to be broken tomo. Gla

Moving back up now good luck

Yes zgrace keep up the good work...we appreciate it... thank you very much

hTtps://www.valirx.com/wp-content/uploads/2020/08/Valirx-Plc-August-2020-Answers.pdf

Good luck all!

antfolli looks like you want a lower entry? why do you constantly come on and talk bs when you have no interest in this share? im sure the Japanese know something you dont for them to have an interest in VAL. Please give it a rest!

I agree Mr nation also if val201 wasnt as good then why would they use val201 as a potential cure for covid-19 also I agree there are too many trolls on this bb. Best to ignore them. Best to hold for gold. Good luck all

Good luck all

Mathsfrop for u it may not...but for me it says alot of things. Each to their own. Tgey have spent such a long time to get this far. If it was not worthwhile it would have been stopped a long time ago. So far we know its well tolerated and safe. The rest we shall find out soon. You have to be in it to win it...gla

They will announce HEADLINE newa in Q3 thereafter detailed analysis in Q4... what does that say to you? Must be good news or otherwise why bother to send more details in Q4. Gla

The Phase 1/2 clinical trial of VAL201 in the treatment of men with prostate cancer was closed to further recruitment on 27 January 2020, with recruitment standing at a total of 12 patients dosed across 5 cohorts. The dose escalation was carried out from 0.5 mg/kg up to 8 mg/kg with dosing being carried out once a week.



The trial considered the safety and tolerability of drug administration, alongside pharmacokinetics and disease impact. Although the COVID-19 pandemic lockdown initially cast concern on the time schedules for data verification processes, the project remains on track to release headline results within Q3 2020, which will provide basic details of safety, tolerability and disease impact. More detailed observations on the pharmacokinetics and complete summaries of patient demographics, biochemistry and study conduct will be available when the Clinical Study Report is completed in Q4 2020

Should move towards more realistic value before news. Hope we can get to 0.60p today...good luck all

0.50p to buy moving up nicely gla

Nice start. Hope we can breach 0.50p today....gla

Hopefully we can breach 0.50p today gla